Skip to main content

Biotechnology Stocks Trending on New Developments 2018

CORAL GABLES, FL / ACCESSWIRE / August 6, 2018 / Earnings season continues to roll on this week as a number of companies report second quarter results. One of the standout sectors has been biotechnology and health-related stocks. In fact over the last 3 months, the Health Care Select Sector SPDR Fund (XLV) has been climbing back toward its 52 week high.

Likewise, both the SPDR S&P Biotech ETF (XBI) and the iShares NASDAQ Biotechnology Index ETF (IBB) have maintained their 2018 uptrend despite periodic consolidation throughout the year. With this in mind, investors have focused attention on the biotech and health sectors for new opportunities where some small-cap issuers have begun to find a more active market during recent weeks.

GT Biopharma (GTBP) announced a Material Transfer Agreement between a Major Pharmaceutical Company and Dr. Daniel Vallera, Director, Section of Molecular Cancer Therapeutics at the Masonic Cancer Center, University of Minnesota. This Major Pharmaceutical Company will be supplying a formulation of their multibillion-dollar, widely prescribed oncology drug, which has been approved for use in several hematologic malignancies to Dr. Vallera to be used in this study.

The companies OXS-1550 targets two antigens on cancer cells and contains a cytotoxic payload, which increases the probability that it will kill the cancer cells. Initial pre-clinical work performed by Dr. Vallera suggests a much greater effect when OXS-1550 is given in combination with this established oncology drug.

Shares of GT Biopharma have been in an uptrend for the last few weeks. In July GT shares were under $1.50 and Thursday's session had GT Biopharma hitting highs of $2.18.

For More information On GT Biopharma, Click Here

Neovasc, Inc . (NASDAQ: NVCN) announced today the publication of the manuscript, "Safety and efficacy of the Reducer: A multicenter clinical registry - REDUCE study" in the International Journal of Cardiology.

"The publication is another 'real-world,' non-randomized study which demonstrates clinical results in an additional 141 enrolled patients, that are remarkably consistent with the results of the COSIRA randomized sham-controlled clinical trial. This recent manuscript published in the International Journal of Cardiology is a testament to the benefits of the Reducer as a safe device, which can provide substantial quality of life improvements in patients with refractory angina, who do not have other suitable treatment alternatives," stated Fred Colen, Neovasc's President, and Chief Executive Officer.

Shares were up 18% in the premarket on Monday.

For More Information On Neovasc, Click Here

Antares Pharma, Inc. (NASDAQ: ATRS) announced this morning that it has entered into an agreement with Pfizer Inc. (''Pfizer'') to develop a combination drug-device rescue pen. This rescue pen will utilize the Antares QuickShot® auto-injector and an undisclosed Pfizer drug. Pfizer will pay for the development of the product and will be responsible for obtaining FDA approval of the combination product.

According to press, the parties intend to enter into a separate supply agreement pursuant to which Antares will provide fully packaged commercial ready finished product to Pfizer at cost plus margin and Pfizer will then be responsible for commercializing the product in the United States, pending FDA approval. Antares will then receive royalties on net sales on the combination product.

Shares were up over 3% in the premarket

For More Information On Antares Pharma, Inc., Click Here.

About marijuanastocks.com

MarijuanaStocks.com is the leading web destination for all things cannabis. Investors can find marijuana-related financial, medical, legal, and social news anytime day or night. Writers are invited to submit cannabis related articles for publication.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. MAPH Enterprises LLC which owns www.MarijuanaStocks.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release.

MAPH Enterprises LLC, which owns www.MarijuanaStocks.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. MAPH Enterprises LLC, which owns www.MarijuanaStocks.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. An affiliate of MarijuanaStocks.com - MIDAM VENTURES LLC., a Florida Corporation that has been compensated $200,000.00 by GT Biopharma Inc. for a period beginning July 16, 2018 and ending August 16, 2018 to publicly disseminate information about (GTBP). We own zero shares. We may buy or sell additional shares of (GTBP) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

Contact Information:

pr@marijuanastocks.com

SOURCE: MarijuanaStocks.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.